Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKatarina MicinFNFelipe NovoaAAAna C. Ayupe

Discussion

Loading...

Member takes

Overview

Prospective analysis evaluates scMRD's effectiveness in detecting residual leukemia and predicting disease relapse in AML patients under targeted therapies.

Key Points

  • This research aims to assess the clinical utility of the single-cell MRD (scMRD) assay in monitoring AML patients' disease status.
  • Analyzed a cohort of 21 AML patients receiving routine induction therapy.
  • Collected and processed bone marrow aspirates enriched for CD117+ cells for scMRD assay using Mission Bio's Tapestri platform.
  • Utilized next-generation sequencing for variant detection and compared results with clinical assays.
  • Detected 345 mutant cells in one case, indicating scMRD's potential to identify residual leukemia despite negative clinical assay results.
  • Demonstrated early detection of mutant clones in HMA+Ven treated patients, correlating with disease progression and relapse.
  • Highlighted the prognostic potential of combining scMRD with existing clinical MRD practices.

Cite This Study

Micin et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6f1https://doi.org/10.1182/blood-2025-280
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 692: Novel single cell and bulk NGS assays for improved assessment of MRD (measurable residual disease) and clonal dynamics in acute myeloid leukemia (AML).2026
  2. 2MRD-seq: A sensitive next generation sequencing-based approach for measurable residual disease detection in acute myeloid leukaemia2025
  3. 3Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples2025
  4. 4Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025
  5. 5A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations